http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0268912-A3
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 1987-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1990-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0268912-A3 |
| titleOfInvention | Pharmaceutical composition comprising alpha-2i-selective adrenergic receptor agonists and the use thereof in memory enhancement |
| abstract | Disclosed is a method of treating memory ndisorders and cognitive decline, e.g., age-related ncognitive decline, in a primate by administering thereto na therapeutically effective amount of an alpha-2 agonist nhaving a high affinity for the alpha-2I subtype, e.g., nguanfacine and guanabenz or a nontoxic, pharmaceutically nacceptable salt thereof. Particularly preferred is the nuse of alpha-2I selective agonists such as guanfacine. |
| priorityDate | 1986-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.